Chemotherapy and Targeted Therapy

The Billion-Dollar Illusion: How Medvi Exploits the Fractured Regulatory Landscape of Telehealth $the-billion-dollar-illusion-how-medvi-exploits-the-fractured-regulatory-landscape-of-telehealth$

The Billion-Dollar Illusion: How Medvi Exploits the Fractured Regulatory Landscape of Telehealth

Pevita Pearce May 31, 2026

In the modern digital economy, the adage "move fast and break things" has found a new, more...

Precision Breakthrough: UCLA Researchers Advance Novel EGFR-Targeted Therapy for Glioblastoma precision-breakthrough-ucla-researchers-advance-novel-egfr-targeted-therapy-for-glioblastoma

Precision Breakthrough: UCLA Researchers Advance Novel EGFR-Targeted Therapy for Glioblastoma

Ali Ikhwan May 31, 2026

In the high-stakes arena of neuro-oncology, glioblastoma multiforme (GBM) has long been considered the "emperor of maladies."...

Precision Meets Productivity: Wellstar and BD Revolutionize Medication Management Through AI Integration precision-meets-productivity-wellstar-and-bd-revolutionize-medication-management-through-ai-integration

Precision Meets Productivity: Wellstar and BD Revolutionize Medication Management Through AI Integration

Evan Lee Salim May 30, 2026

In an era where healthcare systems are increasingly burdened by labor shortages, rising costs, and the complex...

Protecting Innovation in a Borderless Pharma Economy: The New Frontier of Global Intellectual Property protecting-innovation-in-a-borderless-pharma-economy-the-new-frontier-of-global-intellectual-property

Protecting Innovation in a Borderless Pharma Economy: The New Frontier of Global Intellectual Property

Siti Muinah May 30, 2026

In the modern pharmaceutical landscape, the journey of a single molecule from a laboratory bench to a...

Pfizer’s $10 Billion Pivot: Decoding the Strategic Shift Toward Chinese Biotech Innovation pfizers-10-billion-pivot-decoding-the-strategic-shift-toward-chinese-biotech-innovation

Pfizer’s $10 Billion Pivot: Decoding the Strategic Shift Toward Chinese Biotech Innovation

Asro May 30, 2026

In a move that underscores the rapidly evolving architecture of global pharmaceutical R&D, Pfizer has announced an...

Bristol Myers Squibb Stakes Future on Mezigdomide: A New Era in Myeloma Treatment bristol-myers-squibb-stakes-future-on-mezigdomide-a-new-era-in-myeloma-treatment

Bristol Myers Squibb Stakes Future on Mezigdomide: A New Era in Myeloma Treatment

Basiran May 30, 2026

By Jonathan Gardner | Published May 29, 2026 In the high-stakes world of oncology, few franchises have...

The GLP-1 Paradox: Biopharma’s R&D Productivity Rebound Masks Deep Structural Fragility the-glp-1-paradox-biopharmas-rd-productivity-rebound-masks-deep-structural-fragility

The GLP-1 Paradox: Biopharma’s R&D Productivity Rebound Masks Deep Structural Fragility

Suro Senen May 30, 2026

After a prolonged period of "post-pandemic hibernation"—characterized by uneven growth and dwindling R&D returns—the global biopharmaceutical sector...

Biopharma Industry Update: Executive Shifts, Clinical Setbacks, and Strategic Regulatory Wins biopharma-industry-update-executive-shifts-clinical-setbacks-and-strategic-regulatory-wins

Biopharma Industry Update: Executive Shifts, Clinical Setbacks, and Strategic Regulatory Wins

Basiran May 29, 2026

Published May 29, 2026 | Reporting by Ben Fidler The biopharmaceutical landscape continues to demonstrate the high-stakes...

Breaking the Spreadsheet Stranglehold: How AI is Transforming Clinical Trial Data Management breaking-the-spreadsheet-stranglehold-how-ai-is-transforming-clinical-trial-data-management

Breaking the Spreadsheet Stranglehold: How AI is Transforming Clinical Trial Data Management

Rifan Muazin May 29, 2026

In the high-stakes world of pharmaceutical development, where a single Phase 3 clinical trial can represent a...

Pharma Giant Eli Lilly Pivots Toward Infectious Disease with $4 Billion Triple-Acquisition Strategy pharma-giant-eli-lilly-pivots-toward-infectious-disease-with-4-billion-triple-acquisition-strategy

Pharma Giant Eli Lilly Pivots Toward Infectious Disease with $4 Billion Triple-Acquisition Strategy

Muslim May 29, 2026

By Delilah Alvarado Published May 26, 2026 In a strategic maneuver that marks a significant diversification of...

Chemotherapy and Targeted Therapy

The Billion-Dollar Illusion: How Medvi Exploits the Fractured Regulatory Landscape of Telehealth

Precision Breakthrough: UCLA Researchers Advance Novel EGFR-Targeted Therapy for Glioblastoma

Precision Meets Productivity: Wellstar and BD Revolutionize Medication Management Through AI Integration

Protecting Innovation in a Borderless Pharma Economy: The New Frontier of Global Intellectual Property

Pfizer’s $10 Billion Pivot: Decoding the Strategic Shift Toward Chinese Biotech Innovation

Bristol Myers Squibb Stakes Future on Mezigdomide: A New Era in Myeloma Treatment

The GLP-1 Paradox: Biopharma’s R&D Productivity Rebound Masks Deep Structural Fragility

Biopharma Industry Update: Executive Shifts, Clinical Setbacks, and Strategic Regulatory Wins

Breaking the Spreadsheet Stranglehold: How AI is Transforming Clinical Trial Data Management

Pharma Giant Eli Lilly Pivots Toward Infectious Disease with $4 Billion Triple-Acquisition Strategy

You may have missed

Ibuprofen: Beyond Pain Relief – Unveiling its Unexpected Anti-Cancer Potential

A Paradigm Shift in HIV Care: Gilead and Merck’s Once-Weekly Regimen Passes Phase 3 Milestone

Beyond Wrinkles: The Emerging Role of Botox in Revolutionizing Scar Management

The Radiology Crisis: Escalating Costs and Workforce Shortages Threaten Patient Care